BRIEF published on 03/24/2025 at 08:35, 1 year 5 months ago Abivax Publishes its Financial Results for 2024 Financial Results Biotechnology Research And Development Treasury Clinical Trials
PRESS RELEASE published on 03/24/2025 at 08:30, 1 year 5 months ago Abivax Announces Full Year 2024 Financial Results Abivax announces full year 2024 financial results, cash balance of EUR 144.2M, ABTECT trial progress. CEO optimistic about 2025 milestones and financial outlook Financial Results Cash Position Abivax ABTECT Trial Clinical Progress
BRIEF published on 03/14/2025 at 15:21, 1 year 6 months ago JP Morgan Chase Reduces Stake in ABIVAX Actions Abivax Regulation Threshold Crossing JP Morgan Chase
BRIEF published on 03/13/2025 at 12:43, 1 year 6 months ago JP Morgan Crosses Threshold in ABIVAX Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF published on 02/25/2025 at 18:05, 1 year 6 months ago ABIVAX: Information on capital and voting rights as of January 31, 2025 Euronext Paris Share Capital Voting Rights Abivax Finances
BRIEF published on 02/21/2025 at 08:35, 1 year 6 months ago Abivax to Hold Expert Webcast on Ulcerative Colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial Webcast Event
PRESS RELEASE published on 02/21/2025 at 08:30, 1 year 6 months ago Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Abivax to host Key Opinion Leader (KOL) webcast featuring Dr. David Rubin on March 17, 2025, discussing ulcerative colitis treatment landscape and ABTECT Phase 3 Trial Abivax Ulcerative Colitis Webcast ABTECT Phase 3 Trial Key Opinion Leader
BRIEF published on 02/18/2025 at 10:08, 1 year 6 months ago Crossing of threshold at ABIVAX: statement from Sofinnova Voting Rights Abivax Threshold Crossing Product Development Sofinnova Partners
BRIEF published on 01/28/2025 at 08:35, 1 year 7 months ago Abivax unveils its financial calendar for 2025 Financial Results Biotechnology Half-yearly Report Financial Calendar Abivax
PRESS RELEASE published on 01/28/2025 at 08:30, 1 year 7 months ago Abivax Publishes 2025 Financial Calendar Abivax publishes its 2025 financial calendar, detailing key financial communications throughout the year. The company is focused on developing therapies for chronic inflammatory diseases Biotechnology Abivax Therapeutics Chronic Inflammatory Diseases 2025 Financial Calendar
Published on 09/17/2026 at 10:00, 1 hour 26 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 11 hours 41 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 13 hours 56 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 18 hours 31 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 20 hours 26 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/17/2026 at 11:00, 26 minutes ago ABB Ltd: ABB share buybacks - September 10, 2026 - September 16, 2026
Published on 09/17/2026 at 10:41, 45 minutes ago elumeo SE successfully completes a cash capital increase
Published on 09/17/2026 at 10:40, 46 minutes ago Making the Most of Every Ray, Powering the Unpowered: 2026 Global Low-Carbon Industry Forum Explores Pathways to Bridge the Electricity Gap
Published on 09/17/2026 at 10:05, 1 hour 21 minutes ago Geely Farizon Debuts Full-Spectrum Electric Commercial Vehicle Lineup at IAA Transportation 2026
Published on 09/17/2026 at 10:05, 1 hour 21 minutes ago Avalara Appoints Claire Goad as General Manager of E-Invoicing and Live Reporting
Published on 09/16/2026 at 17:45, 17 hours 41 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 4 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 17 hours ago Report on the Combined General Meeting of the 10th of September 2026
